KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (ONC) Equity Ratio (2016 - 2025)

Historic Equity Ratio for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to 0.54.

  • BeOne Medicines' Equity Ratio fell 819.26% to 0.54 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54, marking a year-over-year decrease of 819.26%. This contributed to the annual value of 0.56 for FY2024, which is 763.81% down from last year.
  • Per BeOne Medicines' latest filing, its Equity Ratio stood at 0.54 for Q3 2025, which was down 819.26% from 0.6 recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Equity Ratio peaked at 0.8 during Q4 2022, and registered a low of 0.54 during Q3 2025.
  • Moreover, its 5-year median value for Equity Ratio was 0.65 (2021), whereas its average is 0.65.
  • In the last 5 years, BeOne Medicines' Equity Ratio soared by 1130.66% in 2022 and then plummeted by 2380.62% in 2023.
  • Quarter analysis of 5 years shows BeOne Medicines' Equity Ratio stood at 0.72 in 2021, then rose by 11.31% to 0.8 in 2022, then dropped by 23.81% to 0.61 in 2023, then decreased by 7.64% to 0.56 in 2024, then decreased by 3.87% to 0.54 in 2025.
  • Its Equity Ratio was 0.54 in Q3 2025, compared to 0.6 in Q2 2025 and 0.6 in Q1 2025.